financetom
Business
financetom
/
Business
/
Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell
Jun 18, 2025 6:14 AM

08:47 AM EDT, 06/18/2025 (MT Newswires) -- Aptevo Therapeutics ( APVO ) said Wednesday that its mipletamig combination therapy achieved an 85% remission rate in frontline Acute myeloid leukemia patients.

The triplet therapy with venetoclax and azacitidine showed no dose-limiting toxicities or cytokine release syndrome, the company said.

Mipletamig's approach demonstrated strong efficacy and safety in patients unfit for chemotherapy, according to the phase 1b/2 Rainer trial results, Aptevo said.

The company also said three patients, including one previously ineligible for transplant, achieved complete remission, including MRD-negative status.

Group 3 of the trial is nearing full enrollment at the highest dose level tested, with the company optimistic about mipletamig's potential, it said.

Shares of the company were up over 141% in recent Wednesday premarket activity.

Price: 6.82, Change: +4.00, Percent Change: +141.84

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Coya Therapeutics Shares Fall After Phase 2 Alzheimer's Disease Study Results
Coya Therapeutics Shares Fall After Phase 2 Alzheimer's Disease Study Results
Nov 3, 2024
12:20 PM EDT, 10/29/2024 (MT Newswires) -- Coya Therapeutics ( COYA ) shares fell nearly 23% in recent Tuesday trading after the company reported results from its phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease. The placebo-controlled study evaluated two dosing regimens of subcutaneous low-dose interleukin-2, or IL-2. The trial met its primary and...
Cognizant Selected as Alnylam's IT Services Provider
Cognizant Selected as Alnylam's IT Services Provider
Nov 3, 2024
12:25 PM EDT, 10/29/2024 (MT Newswires) -- Cognizant Technology Solutions ( CTSH ) said Tuesday it was selected to become Alnylam Pharmaceuticals' ( ALNY ) IT managed services provider. Cognizant said it would be responsible for managing Alnylam's global infrastructure and operations, cloud, security, platforms, applications, and advanced data analytics. The company did not disclose the financial terms of the...
Soccer-Amorim set to be new Man Utd boss as Sporting confirm interest
Soccer-Amorim set to be new Man Utd boss as Sporting confirm interest
Nov 3, 2024
Oct 29 (Reuters) - Ruben Amorim is set to become the next manager of Manchester United ( MANU ) with the Premier League club prepared to pay Sporting the 10 million euros ($10.79 million) release clause, the Portuguese club said on Tuesday. The news comes a day after the team sacked Erik ten Hag with United languishing in 14th place...
Lucid Group to Begin US Orders for Lucid Gravity SUV on Nov. 7
Lucid Group to Begin US Orders for Lucid Gravity SUV on Nov. 7
Nov 3, 2024
12:35 PM EDT, 10/29/2024 (MT Newswires) -- Lucid Group ( LCID ) said Tuesday it will start taking orders in the US for the Lucid Gravity SUV on Nov. 7. Orders will open initially for the Grand Touring variant, starting at $94,900, with production set to begin in late 2024, the electric vehicle maker said. The production of the Gravity...
Copyright 2023-2025 - www.financetom.com All Rights Reserved